Skip to content

Monopar Therapeutics MNPR Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$3.89M-48.3%-$5.2M+52.4%-$3.44M-164%-$2.45M-43.0%-$2.62M-59.9%
$1.69M+24.9%$1.1M+296%$1.1M+452%$1.28M+283%$1.36M+312%
-$287.14K+62.8%$738.68K-34.9%-$770.97K-148%
$187.04K-62.7%-$709.4K-2,484%$107.24K+3,721%$84.72K+270%$502.03K+1,300%
-$3.47M+38.7%-$3.37M-68.6%-$2.09M-94.7%-$1.08M+35.7%-$5.66M-242%
$40.84M+2,021%$78.29M+446%$5.73M$1.21M+49,950%$1.93M+95.9%
$35.25M+2,103%$16.1M$3.6M+265%$2.4M$1.6M
-$5.58M-1,614%-$62.19M-334%-$2.13M-316%$1.19M+49,101%-$325.83K+66.9%
$0$0-100%$0$0$0-100%
$200.2K+52.7%$298.09K+345%$381.56K+2,208%$321.56K+3,115%$131.13K+1,121%
-$200.2K-73.1%$0-100%$92.39M-$316.85K-$115.68K-104%
-$31.63K-58,470%$99.5K$376-91.6%-$2.55K-$54+96.7%
-$9.29M-52.2%$88.18M+88,411%-$209.47K+87.6%-$6.1M-1,227%
$799.63K+569%$119.51K+5,202%
$187.04K-62.7%-$709.4K-2,484%$107.24K+3,721%$84.72K+270%$502.03K+1,300%
$0-100%$0-100%$0-100%$0-100%
$40.84M+2,021%$78.29M+446%$5.73M$1.21M+49,950%$1.93M+95.9%
$35.25M+2,103%$16.1M$3.6M+265%$2.4M$1.6M
-$31.63K-58,470%$99.5K$376-91.6%-$2.55K-$54+96.7%
-$0-100%$3M
$25-97.1%$5K$0$3.58K$850+120%
$291.73K+2,846%$164.09K$0$117.44K$9.9K

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Monopar Therapeutics generate?
Monopar Therapeutics (MNPR) generated -$10.0M in operating cash flow over the trailing twelve months.
Where does Monopar Therapeutics's cash flow data come from?
Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.